Entera Bio Board Member, Miranda Toledano, to Assume Role of Chief Business Officer, Chief Financial Officer, and Head of Corporate Strategy
May 16 2022 - 7:00AM
Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of
orally delivered large molecule therapeutics, today announced the
appointment of Miranda Toledano, one of Entera’s existing board
members, as Chief Business Officer, Chief Financial Officer, and
Head of Corporate Strategy, effective immediately.
“Miranda is an accomplished leader in the
biotechnology industry with almost 25 years of C-level leadership,
principal investment and capital markets experience,” commented
Spiros Jamas, Chief Executive Officer of Entera Bio. “Ms. Toledano,
as a member of our Board of Directors since 2018, has an extensive
understanding of Entera’s pipeline and vision. I am excited by the
benefit the company will gain with Miranda as part of our
leadership team. Her strategic experience is a perfect fit,
as we progress through our global partnership discussions and
development of our proprietary oral delivery platform.”
“I am excited to join Entera's management team
at this critical juncture in the company’s history, as our lead
program EB613 prepares to fulfill its potential as the first oral
anabolic for the treatment of post-menopausal women at high risk of
osteoporosis,” commented Miranda Toledano. “EB613 has shown
compelling efficacy and safety and there is a clear unmet need for
an oral agent to expand the PTH therapeutic class, which is well
validated for close to 20 years. Further, Entera will continue
to work with strategic partners to broaden our technology to
additional high unmet need therapeutic categories, where oral
delivery of large molecules is warranted.”
Ms. Toledano most recently served as Chief
Operating Officer, Chief Financial Officer and Director of TRIGR
Therapeutics, an oncology focused, clinical stage bispecific
antibody company acquired by Compass Therapeutics (Nasdaq: CMPX) in
June 2021. At TRIGR, Miranda oversaw the clinical development and
led strategic execution, including a $117 million China License
Transaction and acquisition by CMPX. Previously, Ms. Toledano
served as Head of Healthcare Investment Banking at MLV & Co.
(acquired by B. Riley FBR & Co.), where she completed biotech
equity financings (IPOs, ATMs, and follow-ons) totaling over $4
billion in aggregate value. Earlier in her career, Ms. Toledano
served as vice president in the investment group of Royalty Pharma.
Ms. Toledano currently serves as a member of our board of directors
as well as a member of the board of directors of Compass
Therapeutics (Nasdaq: CMPX), Journey Medical (Nasdaq: DERM) and
NEXGEL (Nasdaq: NXGL). Ms. Toledano holds a B.A. in Economics
from Tufts University and an MBA in Finance and Entrepreneurship
from the NYU Stern School of Business.
About Entera BioEntera is a
leader in the development of orally delivered large molecule
therapeutics for use in areas with significant unmet medical need
where adoption of injectable therapies is limited due to cost,
convenience and compliance challenges for patients. The Company’s
proprietary, oral drug delivery technology is designed to address
the technical challenges of poor absorption, high variability, and
the inability to deliver large molecules to the targeted location
in the body through the use of a synthetic absorption enhancer to
facilitate the absorption of large molecules, and protease
inhibitors to prevent enzymatic degradation and support delivery to
targeted tissues. The Company’s most advanced product candidates,
EB613 for the treatment of osteoporosis and EB612 for the treatment
of hypoparathyroidism are in clinical development. The Company
recently completed the Phase 2 study for EB613. Entera also
licenses its technology to biopharmaceutical companies for use with
their proprietary compounds and, to date, has established a
collaboration with Amgen Inc. For more information on Entera Bio,
visit www.enterabio.com.Forward Looking
StatementsVarious statements in this release are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements (other
than statements of historical facts) in this press release
regarding our prospects, plans, financial position, business
strategy and expected financial and operational results may
constitute forward-looking statements. Words such as, but not
limited to, “anticipate,” “believe,” “can,” “could,” “expect,”
“estimate,” “design,” “goal,” “intend,” “may,” “might,”
“objective,” “plan,” “predict,” “project,” “target,” “likely,”
“should,” “will,” and “would,” or the negative of these terms and
similar expressions or words, identify forward-looking statements.
Forward-looking statements are based upon current expectations that
involve risks, changes in circumstances, assumptions and
uncertainties. Forward-looking statements should not be read as a
guarantee of future performance or results and may not be accurate
indications of when such performance or results will be
achieved.
Important factors that could cause actual
results to differ materially from those reflected in Entera’s
forward-looking statements include, among others: changes in our
interpretation of the 3-month biomarker data from the Phase 2
clinical trial of EB613, the timing of data readouts from the Phase
2 clinical trial of EB613, the full results of the Phase 2 clinical
trial of EB613 and our analysis of the full results from our Phase
2 clinical trial of EB613, the FDA’s interpretation and review of
our results from and analysis of our Phase 2 trial of EB613,
unexpected changes in our ongoing and planned preclinical
development and clinical trials, the timing of and our ability to
make regulatory filings and obtain and maintain regulatory
approvals for our product candidates; the potential disruption and
delay of manufacturing supply chains, loss of available workforce
resources, either by Entera or its collaboration and laboratory
partners, due to travel restrictions, lay-offs or forced closures
or repurposing of hospital facilities; impacts to research and
development or clinical activities that Entera is contractually
obligated to provide, such as those pursuant to Entera’s agreement
with Amgen; overall regulatory timelines, if the FDA or other
authorities are closed for prolonged periods, choose to allocate
resources to review of COVID-19 related drugs or believe that the
amount of Phase 2 clinical data collected are insufficient to
initiate a Phase 3 trial, or a meaningful deterioration of the
current political, legal and regulatory situation in Israel or the
United States; the availability, quality and timing of the data
from the Phase 2 clinical trial of EB613 in osteoporosis patients;
the size and growth of the potential market for EB613 and Entera’s
other product candidates including any possible expansion of the
market if an orally delivered option is available in addition to an
injectable formulation; the scope, progress and costs of developing
Entera’s product candidates including EB612 and GLP-2; Entera’s
reliance on third parties to conduct its clinical trials; Entera’s
expectations regarding licensing, business transactions and
strategic collaborations; Entera’s operation as a development stage
company with limited operating history; Entera’s ability to
continue as a going concern absent access to sources of liquidity;
Entera’s expectations regarding its expenses, revenue, cash
resources, liquidity and financial condition; Entera’s ability to
raise additional capital; Entera’s interpretation of FDA feedback
and guidance and how such guidance may impact its clinical
development plans; Entera’s ability to obtain and maintain
regulatory approval for any of its product candidates; Entera’s
ability to comply with Nasdaq’s minimum listing standards and other
matters related to compliance with the requirements of being a
public company in the United States; Entera’s intellectual property
position and its ability to protect its intellectual property; and
other factors that are described in the “Cautionary Statements
Regarding Forward-Looking Statements,” “Risk Factors” and
“Management’s Discussion and Analysis of Financial Condition and
Results of Operations” sections of Entera’s filings with the SEC
and available free of charge on the SEC’s website at
http://www.sec.gov. Additional factors may be set forth in those
sections of Entera’s Annual Report on Form 10-K for the year ended
December 31, 2021 (the “Annual Report”), filed with the SEC in the
first quarter of 2022. In addition to the risks described above and
in Entera’s Annual Report and Current Reports on Form 8-K and other
filings with the SEC, other unknown or unpredictable factors also
could affect Entera’s results. There can be no assurance that the
actual results or developments anticipated by Entera will be
realized or, even if substantially realized, that they will have
the expected consequences to, or effects on, Entera. Therefore, no
assurance can be given that the outcomes stated in such
forward-looking statements and estimates will be achieved. Entera
cautions investors not to rely on the forward-looking statements
Entera makes in this press release. The information in this release
is provided only as of the date of this release, and Entera
undertakes no obligation, to update or revise publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise, except to the extent required by
law.
Contact:Nicole JonesCG
Capital404-736-3838entx@cg.capital
NexGel (NASDAQ:NXGL)
Historical Stock Chart
From Apr 2024 to May 2024
NexGel (NASDAQ:NXGL)
Historical Stock Chart
From May 2023 to May 2024